Autolus Therapeutics plc (NASDAQ: AUTL) is 63.68% higher on its value in year-to-date trading and has touched a low of $1.60 and a high of $3.79 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AUTL stock was last observed hovering at around $3.19 in the last trading session, with the day’s loss setting it -0.08% off its average median price target of $6.00 for the next 12 months. It is also 74.08% off the consensus price target high of $12.00 offered by 11 analysts, but current levels are -15.19% lower than the price target low of $2.70 for the same period.
Currently trading at $3.11, the stock is 40.06% and 54.53% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.46 million and changing -2.51% at the moment leaves the stock 32.14% off its SMA200. AUTL registered 14.76% gain for a year compared to 6-month loss of 35.22%. The firm has a 50-day simple moving average (SMA 50) of -$4.38 and a 200-day simple moving average (SMA200) of $0.21.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
The stock witnessed a 79.77% gain in the last 1 month and extending the period to 3 months gives it a 64.55%, and is 5.42% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.34% over the week and 10.85% over the month.
Autolus Therapeutics plc (AUTL) has around 399 employees, a market worth around $503.51M and $6.40M in sales. Distance from 52-week low is 94.37% and -17.94% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.10%).
Autolus Therapeutics plc (AUTL) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Autolus Therapeutics plc (AUTL) is a “Overweight”. 11 analysts offering their recommendations for the stock have an average rating of 2.00, where 3 rate it as a Hold and 0 think it is a “Overweight”. 8 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Autolus Therapeutics plc is expected to release its quarterly report on 08/10/2023.The EPS is expected to grow by 20.50% this year
Autolus Therapeutics plc (AUTL) Top Institutional Holders
The shares outstanding are 173.07M, and float is at 158.45M with Short Float at 0.54%.
Autolus Therapeutics plc (AUTL): Who are the competitors?
The company’s main competitors (and peers) include Novan Inc. (NOVN) that is trading -57.30% down over the past 12 months and Bristol-Myers Squibb Company (BMY) that is -14.64% lower over the same period. Gilead Sciences Inc. (GILD) is 24.18% up on the 1-year trading charts.